eigerbioadmin

»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 156 blog entries.
15 04, 2019

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors

2019-04-15T12:26:41+00:00

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors PALO ALTO, Calif., April 15, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Amit K. Sachdev, JD to its Board [...]

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors2019-04-15T12:26:41+00:00
11 04, 2019

Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019

2019-04-11T21:56:39+00:00

Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019 Improved Tolerability in HDV-infected Patients vs Historical Peginterferon Alfa Post-treatment Endpoint Results to be Discussed with Regulatory Agencies PALO ALTO, Calif., April 11, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused [...]

Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 20192019-04-11T21:56:39+00:00
26 03, 2019

Eiger BioPharmaceuticals to Participate in Conferences in April

2019-03-26T13:24:24+00:00

Eiger BioPharmaceuticals to Participate in Conferences in April PALO ALTO, Calif. – March 26, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will present at upcoming investor, scientific, and orphan drug conferences in April. C. Wainwright Global [...]

Eiger BioPharmaceuticals to Participate in Conferences in April2019-03-26T13:24:24+00:00
25 03, 2019

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019

2019-03-25T17:57:47+00:00

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019 Statistically Significant Reduction in Hyperinsulinemic Hypoglycemia Reduced Rates of Hypoglycemia and Rescue in Outpatient Setting PALO ALTO, Calif., March 25, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization [...]

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 20192019-03-25T17:57:47+00:00
20 03, 2019

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019

2019-03-20T13:29:54+00:00

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019 PALO ALTO, Calif., March 20, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the [...]

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 20192019-03-20T13:29:54+00:00
14 03, 2019

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

2019-03-14T22:50:48+00:00

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update Began 2019 with $100.4 million in cash, cash equivalents & short-term investmentsEnrollment of Phase 3 D-LIVR Study in HDV planned by end of 2019NDA and MAA filings for Progeria and Progeroid Laminopathies planned in 2019 PALO ALTO, Calif., March 14, 2019 [...]

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update2019-03-14T22:50:48+00:00
13 03, 2019

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019

2019-03-13T14:34:05+00:00

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019 36% Durable Virologic Response at 24 Weeks Post-Treatment PALO ALTO, Calif., March 13, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced a late-breaker [...]

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 20192019-03-13T14:34:05+00:00
11 03, 2019

Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit

2019-03-11T15:07:06+00:00

Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit PALO ALTO, Calif., March 11, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the Jefferies [...]

Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit2019-03-11T15:07:06+00:00
4 03, 2019

Clinigen and Eiger BioPharmaceuticals launch worldwide Managed Access Program for lonafarnib for patients with Progeria and Progeroid Laminopathies

2019-03-04T15:41:48+00:00

Clinigen and Eiger BioPharmaceuticals launch worldwide Managed Access Program for lonafarnib for patients with Progeria and Progeroid Laminopathies Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR, ‘Eiger’) to launch a worldwide lonafarnib Managed Access Program for patients with Progeria and Progeroid Laminopathies.Progeria, also [...]

Clinigen and Eiger BioPharmaceuticals launch worldwide Managed Access Program for lonafarnib for patients with Progeria and Progeroid Laminopathies2019-03-04T15:41:48+00:00
27 02, 2019

Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer

2019-02-27T14:57:39+00:00

Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer PALO ALTO, Calif., February 27, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Dr. Stephana Patton as the Company’s General [...]

Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer2019-02-27T14:57:39+00:00